Emerging medical treatment for angina pectoris

Expert Opinion on Emerging Drugs

Volumn 15, Issue 2, 2010, Pages 283-298

  Fernandez, Stanley F ^a   Tandar, Anwar ^a   Boden, William E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti anginal agents; Anti ischemic agents; Stable angina

Indexed keywords

4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ALINIDINE; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FASUDIL; FIBROBLAST GROWTH FACTOR; IVABRADINE; METOPROLOL; NICORANDIL; NIFEDIPINE; NITRATE; PERHEXILINE; PLACEBO; RANOLAZINE; TRIMETAZIDINE; UNINDEXED DRUG; VASCULOTROPIN; VERAPAMIL; ZATEBRADINE;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN VASOSPASM; BURNING SENSATION; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENERGY METABOLISM; EXERCISE TOLERANCE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MEDLINE; MORBIDITY; MORTALITY; NAUSEA; NEUROPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOPSIA; POSTMARKETING SURVEILLANCE; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS NODE; STABLE ANGINA PECTORIS; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL DISORDER; VOMITING;

ANGINA PECTORIS; ANIMALS; CARDIOVASCULAR AGENTS; DRUGS, INVESTIGATIONAL; GENE THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECURRENCE; TREATMENT OUTCOME;

EID: 77952801163     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903544482     Document Type: Review

References (112)

1. Silverman ME. William Heberden and some account of a disorder of the breast. Clin Cardiol 1987;10:211-213
2. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline update for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-168
3. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2010;119:480-486
4. Fox K, Garcia MA, Ardissino D, et al. Task force on the management of stable angina pectoris of the European Society of Cardiology. ESC committee for practice guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381 (Pubitemid 43998110)
5. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516
6. Daly CA, Clemens F, Sendon JL, et al. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:1011-1022
7. Pepine CJ, Abrams J, Marks RG, et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994;74:226-231
8. Serruys PW, Unger F, Sousa JE, et al. Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124 (Pubitemid 32285232)
9. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Comparison with a previously untreated population sample. Drugs 1986;31(Suppl 1):47-51
10. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-5410
11. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974
12. North of England Stable Angina Guideline Development Group. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. BMJ 1996;312:827-832
13. Snow V, Barry P, Fihn SD, et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;141:562-567
14. Basu SK, Kinsey CD, Miller AJ, et al. Improved efficacy and safety of controlled-release diltiazem compared to nifedipine may be related to its negative chronotropic effect. Am J Ther 2000;7:17-22
15. Subramanian VB, Bowles MJ, Khurmi NS, et al. Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. Acta Med Scand Suppl 1984;681:61-73
16. Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999;83:507-514
17. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapmil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-785
18. Daniel GW, Malone DC. Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs. J Manag Care Pharm 2007;13:142-154
19. McCormack JG, Marr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-142
20. MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e26-32
21. Mugelli A. The role of the pacemaker current If in cardiovascular pharmacology. Pharmacol Res 2006;53:397-398
22. Madaule P, Axel R. A novel ras-related gene family. Cell 1985;41:31-40
23. Lai A, Frishman WH. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 2005;13:285-292
24. Sentex E, Sergiel JP, Lucien A, et al. Is the cytoprotective effect of trimetazidine associated with lipid metabolism. Am J Cardiol 1998;82(Suppl 1):18K-24K
25. Mody FV, Singh BN, Mohiuddin IH, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998;82(Suppl 1):42K-9K
26. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy - the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35-42
27. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267-2274
28. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005;4:CD003614
29. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003;14:171-179
30. Pornin M, Harpey C, Allal J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. Clin Trials Metaanal 1994;29:49-56
31. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996;52:273-280
32. Cho YW, Belej M, Aviado DM. Pharmacology of a new antianginal drug: perhexiline. I. Coronary circulation and myocardial metabolism. Chest 1970;58:577-581
33. Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on coronary hemodynamics and myocardial metabolic responses to tachycardia. Circulation 1974;49:887-893
34. Barry WH, Horowitz JD, Smith TW. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Phamacol 1985;85:51-59
35. Grima M, Velly J, Decjer N, et al. Inhibitory effects of some cyclohexylaralkylamines related to perhexiline on sodium influx, binding of [3H]batrachotoxinin A 20-alpha-benzoate and [3H]nitrendipine and on guinea pig left atria contractions. Eur J Pharmacol 1988;147:173-185
36. Rampe D, Wang Z, fermini B, et al. Voltage- and time-dependent block of perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel. J Pharmacol Exp Ther 1995;274:444-449
37. Walker BD, Valenzuela SM, Singleton CB, et al. Inhibition of HERG channels stably expressed in mammalian cell line by the antianginal agent perhexiline maleate. Br J Pharmacol 1999;127:243-251
38. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:193-204
39. Inglis S, Stewart S. Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Eur J Cardiovasc Nurs 2006;5:175-184
40. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382
41. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of Ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. J Am Med Assoc 2004;291:309-316
42. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-316
43. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-575
44. Pham DQ, Mehta M. Ranolazine: a novel agent that improves dysfunctional sodium channels. Int J Clin Pract 2007;61:864-872
45. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-1783
46. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of Ranolazine in patients with chronic angina. J Am Coll Cardiol 2010;53:1510-1516
47. Doring G. Antianginal and antiischemic efficacy of nicorandil in comparison with isosorbide -5 mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S74-81
48. Ciampricotti R, Schotborgh CE, de Kam P-J, et al. A comparison of nicorandil with isosorbide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. American Heart J 2000;139:139-143
49. Di SommaS, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993;7:119-123
50. The SWAN study group. Comparison of the antiischemic and antianginal effects of nicorandil and amlodipine in patients with stable angina pectoris: the SWAN study. Clin and basic cardiol 1999;2:213-217
51. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the longterm efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):30-34
52. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-1275
53. Marquat-Elabz C, Lipsker D, Grosshans E, et al. Prevalence and clinical pathological features of nicorandil-induced oral ulceration. Ann Dermatol Venereol 1999;126:587-590
54. Watson A, Suttie S, Fraser A, et al. Nicorandil associated anal ulceration. Colorectal Dis 2004;6:330-331
55. Egred M, Andron M, Morrison WL. Nicorandil may be associated with gastrointestinal ulceration. BMJ 2006;332:889
56. Abdelraseq AS, Owen CM, Smith L, et al. Nicorandil-associated para-stomal ulceration: case series. Eur J Gastroenterol Hepatol 2006;12:1293-1295
57. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823
58. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536
59. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679
60. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393-405
61. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816
62. Hoppe UC, La Rosee K, Larbig R, et al. Selective inhibition of the pacemaker channel I(f) improves symptoms in severe dilated cardiomyopathy. Clin Res Cardiol 2007;96:243-246
63. Tachibana E, Harada T, Shibuya M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir 1999;141:13-19
64. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002;40:751-761
65. Vicari RM, Chaitman B, Keefe D, et al.; Fasudil Study Group. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-1811
66. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-577
67. Suzuki Y, Shibuya M, Satoh S-I, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:126-132
68. Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001;38:1307-1310
69. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004;24:181-186
70. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297
71. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42:1339-1347
72. Grines CL. The AGENT clinical trials programme. Eur Heart J Suppl 2004;6:E18-23
73. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50:1038-1046
74. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-1511
75. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular 5endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982-988
76. Ruel M, Beanlands RS, Lortie M, et al. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the Endothelial Modulation in Angiogenic Therapy randomized controlled trial. J Thorac Cardiovasc Surg 2008;135:762-770
77. Ripa RS, Wang Y, Jorgensen E, et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006;27:1785-1792
78. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23:298-304
79. Bianchi NO, Bianchi MS, Richard SM. Mitochondrial genome instability in human cancers. Mutat Res 2001;488:9-23
80. Satoh H, Hashimoto K. Electrophysiological study of alinidine in voltage clamped rabbit sino-atrial node cells. Eur J Pharmacol 1986;121:211-219
81. Snyders DJ, Van Bogaert PP. Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Archiv -Eur J Physiol 1987;410:83-91
82. Satoh TO, Yamada M. Multiple inhibitory effects of zatebradine (UL-FS 49) on the electrophysiological properties of retinal rod photoreceptors. Pflugers Arch 2002;443:532-540
83. Gasparini S, DiFrancesco D. Action of the hyperpolarization-activated current (Ih) blocker ZD 7288 in hippocampal CA1 neurons. Pflugers Arch 1997;435:99-106
84. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-398
85. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996;348:1329-1339
86. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
87. Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease; the vascular basis for the treatment of myocardial ischemia study. Circulation 2005;111:1747-1755
88. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
89. European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
90. Hultgren HN, Peduzzi P, Detre K, et al. The 5 year effect of bypass surgery on relief of angina and exercise performance. Circulation 1985;72:V79-83
91. European Coronary Surgery Study Group. Long-term results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 1982;2:1173-1180
92. Coronary Artery Surgery Study Group. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation 1983;68:951-960
93. Stys TP, Lawson WE, Hui JCK, et al. Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris. Am J Cardiol 2002;89:822-824
94. McCullough PA, Silver MA, Kennard ED, et al. Impact on body mass index on outcomes of enhanced external counterpulsation therapy. Am Heart J 2006;151:139.e9-139.e13
95. Pettersson T, Bondesson S, Cojocaru D, et al. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Discord 2006;6:28
96. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33:1833-1840
97. Di Pede F, Lanza GA, Zuin G, et al. Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am J Cardiol 2003;91:951-955
98. Mannheimer C, Eliasson T, Augustinsson L-E, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 1998;97:1157-1163
99. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomized trial: Potential Class Improvement From Intramyocardial Channels. Lancet 2000;356:1705-1710
100. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial. Lancet 1999;354:885-890
101. Salem M, Rotevatn S, Nordrehaug JE. Long-term results following percutaneous myocardial laser therapy. Coron Artery Dis 2006;17:385-390
102. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-48
103. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment-elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-1652
104. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007;49:1027-1034
105. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with ischemic cardiomyopathy. Eur Heart J 1990;11:207-212
106. Belardinelli R, Pucaro A. Trimetazidine improves the contractile response of hibernating myocardium to low dose dobutamine in ischemic cardiomyopathy [abstract 3727]. Circulation 1998;98(Suppl):I-709
107. Kober G, Buck T, Sievert H, et al. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992;13:1109-1115
108. Satoh S, Ueda Y, Koyanagi M, et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 2003;35:59-70
109. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002;105:1545-1547
110. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a marked regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 2001;51:169-177
111. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005;112:1284-1288
112. Syed IS, Sanborn TA, Rosengart TK. Therapeutic angiogenesis: a biologic bypass. Cardiology 2004;101:131-143